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Diabetic Retinopathy and Risk of Heart Failure
Ning Cheung, MBBS,* Jie J. Wang, PHD,*† Sophie L. Rogers, MEPI,* Frederick Brancati, MD, MPH,‡
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ARIC (Atherosclerosis Risk In Communities) Study Investigators
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Objectives The purpose of this study was to examine the association of diabetic retinopathy with incident heart failure (HF).
Background Microvascular disease might play a more prominent role in the pathogenesis of diabetic cardiomyopathy, a ma-
jor cause of HF in diabetes. Whether diabetic retinopathy, a microvascular complication of diabetes, predicts HF
is unclear.
Methods A population-based study included 1,021 middle-aged type 2 diabetic persons with normal renal function and
free of clinical coronary heart disease or HF at baseline. Diabetic retinopathy signs were graded from retinal
photographs. Incident HF events were prospectively identified from hospital stay and death records.
Results There were 125 (12.8%) participants with diabetic retinopathy. After 9-year follow-up, 106 (10.1%) participants
developed incident HF events. Persons with retinopathy were more likely to develop HF (cumulative incidence of
21.6%) than those without retinopathy (cumulative incidence of 8.5%). After controlling for age, gender, race,
smoking, diabetes duration, insulin use, blood pressure, lipid profile, and other risk factors, participants with reti-
nopathy had more than 2.5-fold higher risk of developing HF than those without retinopathy (hazard ratio [HR]
2.71; 95% confidence interval [CI] 1.46 to 5.05). This association remained significant after further adjustments
for glycemic control, carotid atherosclerosis, and serum markers of endothelial dysfunction (HR 2.20, 95% CI
1.08 to 4.47).
Conclusions The presence of diabetic retinopathy signifies an excess risk of HF, independent of known risk factors. This fur-
ther supports a contribution of microvascular disease to the development of HF in people with diabetes. (J Am
Coll Cardiol 2008;51:1573–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.076s
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teart failure (HF) is a major cause of morbidity, hospital
tays, and mortality in diabetic populations (1–3). Although
picardial coronary stenosis and hypertension are strongly
elated to HF risk in the general population, diabetic
earts might fail even in the absence of epicardial
oronary artery disease and other risk factors. This
henomenon has been attributed to diabetic cardiomy-
pathy, a complex and incompletely understood disease
rocess recently linked to dysfunction of the coronary
icrocirculation (4,5). In support of this hypothesis,
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007, accepted November 21, 2007.tudies show that microvascular pathology is common in
he diabetic myocardium, evidenced by presence of mi-
roaneurysms (6) and by quantitative demonstration of
erfusion defects from radiological studies (5,7). Hyper-
lycemia has also been associated with disturbances in
icrovascular homeostasis in the myocardium (e.g., en-
othelial cell apoptosis) (8 –10), which might lead to
yocardial dysfunction in the absence of epicardial cor-
nary disease or systemic hypertension (11,12).
See page 1579
Retinopathy is the most common and specific microvas-
ular complication of diabetes. Previous studies have re-
orted associations of diabetic retinopathy with risks of
ardiovascular diseases, such as stroke and coronary heart
isease (13–17). However, there are only limited data on
hether this microvascular complication is related to HF
isk (18–20). In the MESA (Multi-Ethnic Study of Ath-
rosclerosis), we reported a cross-sectional association be-
ween retinopathy signs and left ventricular concentric
emodeling, a precursor of clinical HF (21). Here, we
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Diabetic Retinopathy and Heart Failure April 22, 2008:1573–8examined prospectively the asso-
ciation of diabetic retinopathy
with incident HF in a population-
based cohort of diabetic persons
free of clinical heart disease.
Methods
Study population. The ARIC
(Atherosclerosis Risk In Com-
munities) study is a population-
ased cohort study that included 15,792 persons, ages 45 to
4 years at recruitment in 1987 to 1989 (22). Retinal
hotographs were first obtained at the third examination
1993 to 1995) (23). Of the 12,642 participants who
eturned for this examination, 1,916 had diabetes mellitus,
efined as fasting serum glucose levels of 7.0 mmol/l,
onfasting levels of 11.1 mmol/l, use of diabetic medica-
ions, or physician diagnosis of diabetes (23). Of these, we
xcluded those whose race was neither white nor African-
merican (n  8) and those with HF at the time of retinal
hotography (n  162) (either taking medication for HF or
ith manifest HF according to the Gothenburg Criteria)
24). In addition, we also excluded participants with prevalent
oronary heart disease (n  221) (25) or renal dysfunction (n
217) (estimated glomerular filtration rate 90 ml/min/
.73 m2) (24), because they are 2 competing causes of HF.
f the remaining 1,308 persons, photographs were gradable
or at least 1 retinopathy sign in 1,021 persons. Character-
stics of participants with and without gradable retinal
hotographs have been described elsewhere (23). Ungrad-
ble retinal photographs were due to either no photographs
r photographs of insufficient quality.
ssessment of diabetic retinopathy. One randomly se-
ected eye was photographed with a 45-degree nonmydriatic
amera and evaluated by masked graders according to
tandardized protocol (13,14,23). Retinopathy was graded
ccording to the Early Treatment of Diabetic Retinopathy
tudy severity scale and defined for analysis as absent or
resent and also as absent, mild (minimal nonproliferative
etinopathy), moderate (moderate nonproliferative retinop-
thy), and severe (severe nonproliferative or proliferative
etinopathy) (23). Individual retinopathy signs and the
resence of macular edema were defined separately.
ssessment of HF. Detailed description of HF ascertain-
ent in the ARIC study and quality control procedures has
een published elsewhere (18,24). In brief, an incident HF
vent was defined as a hospital discharge diagnosis coded as
F (ICD-9, code 428 or 518.4) (hospital stay and emer-
ency room visits) or a death certificate with an underlying
rimary or secondary cause of death coded as HF (ICD-
-CM code 428 or ICD-10 code I50) from the time of
etinal photography (third examination, 1993 to 1995) to
ecember 31, 2003.
ssessment of cardiovascular risk factors. Participants
Abbreviations
and Acronyms
CI  confidence interval
HbA1c  glycosylated
hemoglobin
HR  hazard ratio
IMT  intima-media
thicknessnderwent standardized evaluations for blood pressure and ather cardiovascular risk factors at all examinations (26,27).
or analysis, we used data collected from the third exami-
ation (when retinal photography was performed), except
or data (glycosylated hemoglobin [HbA1c], fibrinogen,
hite blood cells, von Willibrand factor, factor VIII, carotid
ntima-media thickness [IMT]) that were only available
rom the second examination (1990 to 1992) (14). The
ean difference in time between second and third exami-
ations was 3.03 years (95% confidence interval [CI] 3.02
o 3.05).
tatistical analysis. We compared unadjusted survival
urves by absence or presence of retinopathy. Follow-up
ime was defined as the number of days from retinal
hotography to the date of the first HF event, last contact,
r December 31, 2003. We used Cox regression to deter-
ine hazard ratio (HR) and its 95% CI for HF in relation
o diabetic retinopathy, initially controlling for age, gender,
ace, and study center (Model 1). The proportional hazard
ssumption was checked by plotting the “log-minus-log”
lot of the estimated survival functions against log time.
ur multivariate analysis included additional adjustments
or traditional cardiovascular risk factors measured at the
hird examination when retinal photography was performed
Model 2) and further adjustments for glycemic control
HbA1c), carotid atherosclerosis (IMT), and biomarkers of
ndothelial dysfunction (factor VIII and von Willebrand
actor) measured at the second examination (Model 3). In
upplementary analysis, we performed stratified analyses by
ender, race and hypertension status, adjusting for Model 2
ovariates. We also tested for potential interactions for these
ariables.
esults
articipants with retinopathy at baseline were more likely to
e women, African Americans, current smokers, insulin
sers, and to have hypertension and higher levels of serum
bA1c, von Willebrand factor and factor VIII than partic-
pants without retinopathy (Table 1). Over the 8.9 years
SD 2.3) of follow-up, there were 106 incident HF cases
dentified. Of the 125 participants who developed HF, 36
34%) died. Persons with retinopathy were more likely to
evelop HF (cumulative incidence of 21.6%) than those
ithout retinopathy (cumulative incidence of 8.5%), as
hown in Figure 1.
Table 2 shows that after initial adjustments for age,
ender, and race/center (Model 1) and further adjustments
or cardiovascular risk factors (Model 2), the presence of
iabetic retinopathy was significantly associated with inci-
ent HF, with higher risks seen for some specific retinop-
thy lesions, such as retinal microaneurysms and hard
xudates. The association remained significant after further
djustments for HbA1c, carotid IMT, and biomarkers of
ndothelial dysfunction (Model 3).
Stratified analyses showed that the association of retinop-
thy with HF was present in both whites (HR 2.39, 95% CI
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.40 to 25.92), hypertensive (HR 2.22, 95% CI 1.08 to
.54) and normotensive (HR 5.59, 95% CI 1.86 to 16.82)
articipants, and in both women (HR 2.98, 95% CI 1.34 to
.64) and men (HR 3.67, 95% CI 1.22 to 11.01). Potential
nteractions were also tested for these stratified variables and
or glomerular filtration rate, and there were no significant
p  0.10) interactions found.
iscussion
n this prospective cohort study of diabetic persons without
linical heart disease and renal dysfunction, we report an
ssociation of diabetic retinopathy with incident HF events.
articipants with diabetic retinopathy were more than twice
s likely to develop HF as those without retinopathy, even
fter controlling for conventional cardiovascular risk factors,
iabetes duration, glycemic control, carotid atherosclerosis,
nd markers of endothelial dysfunction. This association
as somewhat stronger in people without hypertension than
hose with hypertension.
Our findings are consistent with previous studies that
ave reported associations of diabetic retinopathy with heart
isease. Over 2 decades ago, the Framingham Heart and
ye Study showed that diabetic retinopathy was associ-
ted with prevalent cardiovascular disease (odds ratio
4.3, 95% CI 2.7 to 101.9), an end point that included
F, coronary heart disease, intermittent claudication,
aseline Characteristics of Studyopu ation by Diabetic Retinopathy
Table 1 Baseline Characteristics of StudyPopulation by Diabetic Retinopathy
Diabetic Retinopathy
Absent
(n  854)
Present
(n  125) p Value*
Men, % 47.4 37.6 0.04
African Americans, % 25.4 47.2 0.001
Hypertension, % 49.4 33.6 0.001
Cigarette smoking, current, % 40.8 56.0 0.006
Insulin use, % 41.1 58.9 0.001
Age, yrs 59.8 (5.7) 58.9 (5.2) 0.09
6-yr MABP, mm Hg 91.2 (9.1) 92.1 (10.5) 0.32
Body mass index, kg/m2 30.9 (5.7) 31.5 (6.2) 0.32
Glycosylated hemoglobin, % 6.3 (1.3) 8.6 (2.1) 0.001
HDL cholesterol, mg/dl 45.8 (14.9) 48.8 (16.9) 0.04
Triglyceride, mg/dl 178.5 (125.0) 157.8 (103.6) 0.08
Total cholesterol, mg/dl 209.0 (40.8) 206.9 (42.6) 0.59
Fibrinogen, mg/dl 308.2 (62.2) 308.2 (61.3) 0.99
White cell count, 109 cells/dl 6.4 (2.2) 6.1 (1.8) 0.16
von Willebrand factor, mg/dl 120.2 (44.8) 136.0 (49.6) 0.001
Factor VIII, mg/dl 137.5 (37.5) 153.2 (46.9) 0.001
Creatinine, mg/dl 109.5 (9.2) 110.9 (8.8) 0.11
Common carotid IMT, mm 0.76 (0.18) 0.77 (0.17) 0.69
ata are means (SD) or proportions (%). *The p value on the basis of chi-square (categorical), and
nalysis of variance (continuous), comparing differences for individual variables across diabetic
etinopathy categories.
HDL  high-density lipoprotein; IMT  intima-media thickness; MABP  mean arterial blood
ressure.nd stroke (19). Studies in Finland (16), Milan (15), andhe U.S. (14,28) have all reported an excess risk of
oronary heart disease among diabetic persons with
etinopathy compared with those without retinopathy.
hese studies, however, did not specifically evaluate
ssociations of diabetic retinopathy with HF.
Earlier clinical studies have indicated that diabetic reti-
opathy (or other microvascular complications) is associated
ith left ventricular diastolic dysfunction (29,30) and pres-
nce of diabetic cardiomyopathy (2,31–33). Furthermore,
here is evidence from radiological and histological studies
hat diabetic retinopathy is associated with subclinical cor-
nary microvascular pathologies (6,7,34–37). However,
here are limited prospective data on the relationship of
iabetic retinopathy with clinical HF events. Therefore, our
tudy addresses an important gap in the published data.
We have previously reported an association of retinopathy
igns with incident HF in the general population (HR 1.96,
5% CI 1.51 to 2.54) (18). In this study, the interpretation
f results from sub-group analysis of the diabetic partici-
ants was limited, because a number of important con-
ounders (e.g., renal dysfunction, large artery atherosclero-
is), including ones that are specific for diabetic populations
diabetes duration and glycemic control), were not ac-
ounted for. In addition, retinopathy severity was also not
valuated in our previous analysis. In our current study
pecifically focusing on diabetic participants with longer
ollow-up, we confirm that diabetic retinopathy, even in its
ildest form (minimal nonproliferative), predicts a higher
isk of HF, independent of traditional and nontraditional
Figure 1 Heart Failure Free Survival in
Participants With and Without Diabetic Retinopathy
Participants with diabetic retinopathy were more likely to develop incident heart
failure than those without retinopathy in the Atherosclerosis Risk In Communi-
ties Study.
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Diabetic Retinopathy and Heart Failure April 22, 2008:1573–8ardiovascular risk factors in people free of clinical heart
isease or renal dysfunction at baseline. In addition, findings
n this study also extend support to our previous observation
n the MESA, in which we found that diabetic individuals
ith retinopathy were more likely to have left ventricular
oncentric remodeling, a precursor for HF, as determined
rom cardiac magnetic resonance imaging (odds ratio 1.72,
5% CI 1.20 to 2.47) (21).
As we hypothesized previously, small vessel damage seen
n the retina, reflected as diabetic retinopathy signs, might
epresent widespread systemic microcirculatory disease that
laces an increased impedance burden on the heart, in part
hrough reflected waves (21,38,39). This in turn can lead to
ncreased load to the heart and compromise cardiac
erformance (e.g., impair ventricular emptying and con-
ractility), predisposing the development and manifesta-
ion of clinical HF. Additional studies are clearly needed
o verify our hypothesis and perhaps uncover other
oncirculatory mechanisms (e.g., insulin resistance, sym-
athetic overdrive, oxidative stress, endothelin) that
ould also explain our findings (4,5).
Our findings are important for clinicians who treat or
ounsel patients with diabetes. Routine evaluation of the
etina to detect retinopathy signs presents clinicians the
nique opportunity to directly visualize and assess the actual
athology of microvascular damage caused by diabetes.
ncidence and HRs of Heart Failure by Presence of Diabetic Retino
Table 2 Incidence and HRs of Heart Failure by Presence of Dia
At Risk
(n)
Events
n (%)
Diabetic retinopathy
Absent 854 73 (8.5)
Present 125 27 (21.6)
Retinopathy grade
Absent 854 73 (8.5)
Mild 45 9 (20.0)
Moderate-severe 80 18 (22.5)
Microaneurysms
Absent 873 75 (8.6)
Present 110 25 (22.7)
Retinal hemorrhages
Absent 913 85 (9.3)
Present 93 19 (20.4)
Cotton wool spots
Absent 958 96 (10.0)
Present 54 9 (16.7)
Hard exudates
Absent 954 91 (9.5)
Present 67 15 (22.4)
Macular edema
Absent 972 99 (10.2)
Present 49 7 (14.3)
odel 1: adjusted for age, gender, race, and study center. Model 2: adjusted for Model 1 covariates
ntihypertensive medication use, and serum total cholesterol, high-density lipoprotein (HDL) choles
erum glycosylated hemoglobin, factor VIII, and von Willebrand factor (data obtained at the secon
onfidence interval (CI).lthough the impact of diabetic retinopathy on vision is eell known, the clinical significance of retinopathy signs
eyond the eyes of diabetic patients is less clear. Our study
howed that diabetic persons with retinopathy might have a
reater risk of future HF development. Therefore, it is
ossible, as proposed by the investigators from the Framing-
am Heart and Eye Study over 2 decades ago, that retinop-
thy in people with diabetes might represent microvascular
ysfunction not only in the retina but also in other organs,
uch as the heart (19). The presence of retinopathy in
iabetic patients might indicate a need for a more thorough
ardiac assessment and closer follow-up, a recommendation
hat has been suggested in previous clinical studies of
iabetic patients undertaking cardiac revascularization pro-
edures (20,40–43). In addition, a more careful cardiac
ssessment in asymptomatic people with diabetic retinopa-
hy might also allow detection of subclinical left ventricular
ysfunction, facilitating early implementation of treatments
e.g., beta-blockers, angiotensin-converting enzyme inhibi-
ors) to prevent progression to overt HF.
Strengths of our study include a large population-based
ohort and detailed collection and adjustment of potential
onfounders. Potential limitations of our study should also
e discussed. First, diabetic retinopathy was graded from a
ingle retinal photograph taken without pharmacological
upil dilation, and a significant proportion of photographs
ere ungradable. So, retinopathy might have been under-
, the Atherosclerosis Risk in Communities Study
Retinopathy, the Atherosclerosis Risk in Communities Study
Incident Heart Failure
Model 1 HR
(95% CI)*
Model 2 HR
(95% CI)*
Model 3 HR
(95% CI)*
1.0 1.0 1.0
61 (1.74–3.93) 2.71 (1.46–5.05) 2.20 (1.08–4.47)
1.0 1.0 1.0
99 (1.49–6.03) 3.06 (1.34–6.99) 1.91 (0.65–5.62)
88 (1.70–4.87) 2.48 (1.15–5.32) 2.38 (1.04–5.42)
1.0 1.0 1.0
99 (1.89–4.75) 2.83 (1.45–5.53) 2.69 (1.27–5.70)
1.0 1.0 1.0
51 (1.51–4.19) 1.56 (0.80–3.04) 1.36 (0.65–2.88)
1.0 1.0 1.0
84 (0.92–3.69) 1.18 (0.49–2.87) 0.91 (0.35–2.39)
1.0 1.0 1.0
75 (1.58–4.79) 2.19 (1.07–4.49) 2.33 (1.10–4.93)
1.0 1.0 1.0
37 (0.63–2.95) 1.13 (0.46–2.78) 1.21 (0.49–3.02)
y mass index, smoking status, diabetes duration, insulin use, 6-year mean arterial blood pressure,
d triglycerides. Model 3: adjusted for Model 2 covariates plus carotid intima-media thickness and
ination, 3 years before retinal photography; see Methods). *Adjusted hazard ratio (HR) and 95%pathy
betic
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April 22, 2008:1573–8 Diabetic Retinopathy and Heart Failuressociations, because retinal photography was performed at
he third examination whereas some variables used in our
nalyses were available only at the second examinations
e.g., HbA1c, carotid IMT). Third, we did not have data on
entricular function (e.g., results from echocardiographic
xaminations) to assess whether the predominant cause of
F in our study was due to systolic or diastolic dysfunction.
inally, although in our multivariate analysis we have
djusted for antihypertensive medications and insulin use,
he possibility of residual confounding from the other
edical treatments cannot be totally excluded. For example,
ertain types of hypoglycemic agents (e.g., glitazone class)
ight be associated with a higher risk of HF development
44,45). However, we have no reason to believe these
edications would have a major confounding effect on our
esults, because glitazone has not been known to affect
etinopathy.
onclusions
n summary, we demonstrate a prospective association of
iabetic retinopathy with an increased risk of HF, inde-
endent of diabetes duration, glycemic control, and other
raditional and nontraditional cardiovascular risk factors.
hese findings might provide further evidence to support
microvascular etiology of HF in diabetes and might
uggest that diabetic patients with retinopathy signs
ight warrant a more careful cardiac evaluation and
ollow-up.
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